Skip to main content

Aura Biosciences, Inc.

corporate_fare Company Profile

Aura Biosciences, Inc.

AURA·NASDAQ·Life Sciences·CIK 0001501796

We are a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, designed to preserve organ function. Our primary drug candidate, bel-sar, is in late-stage clinical development for early choroidal melanoma, defined as small choroidal melanoma and/or indeterminate lesions. Bel-sar is also in clinical development for other ocular oncology indications and bladder cancer. We are evaluating bel-sar's safety and efficacy as a potential vision-sparing therapy in our global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. We also plan to assess bel-sar for other solid tumors, starting with metastases to the choroid and bladder cancer, and cancers of the ocular surface. In a Phase 2 study (NCT04417530) for first-line treatment of early choroidal melanoma, 22 patients received suprachoroidal (SC) administration of bel-sar and were monitored over a twelve-month follow-up period for tumor control, visual acuity preservation, and tumor growth rate.

Aura Biosciences, Inc. (NASDAQ:AURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for AURA spans 10-Q, 8-K, S-3, DEF 14A.

Recent high-impact activity:

  • Aura Q3 10-Q: $297.2M Cash Into 1H 2029, Net Loss Widens to $111.4M
  • Aura Q3: CoMpass Treatment Complete, $297M Cash Into 1H 2029, CDMO Deal Signed
  • Aura Biosciences Launches $500M Shelf and $200M ATM Program as It Restructures and Refocuses on Ocular Oncology
  • Aura Biosciences Q2 2026: 20% Workforce Cut and Strategic Pivot to Ocular Oncology
  • Aura Biosciences Q2 2026: Restructuring Sharpens Focus on Ocular Oncology, Cash Runway Extended into 1H 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$106.19M
Diluted EPS
-$1.76
Op. Cash Flow
-$84.74M
Free Cash Flow
-$85.19M
Operating Income
-$112.79M
Cash & Equivalents
$59.52M
Debt / Equity
0.00×
Shares Outstanding
63.59M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-130401

Short Interest & Short Volume

13.67 days to cover

FINRA reported short interest of 10,464,215 shares in AURA as of the October 30, 2026 settlement, a 3.9% decrease from the prior period — about 13.7 days to cover at its recent average daily volume. On November 20, 2026, 72.6% of AURA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,464,215 shares as of October 30, 2026
Change vs prior period▼ 3.9%
Days to cover13.67 at avg daily volume of 765,417
Daily short volume (FINRA facilities)72.6% of 257,546 shares on November 20, 2026
5-day average short volume55.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for AURA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-11.

ATM program1 shelf registration

New $500M Shelf Registration Filed · $200M ATM Program Established

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$6.77 -1.46% today
52-week range · as of 2026-11-09 $4.73 – $9.54
Market cap
$714.99M
Volume
791.1K (1.0× avg)
3-mo avg 803.7K
Live data · 2026-11-22 08:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AURA - Latest Insights

AURA
Nov 09, 2026, 7:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $6.77 info
Change: +$0.210 (+3%) info
Market Cap: $714.99M info
AURA
Nov 09, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $6.77 info
Change: +$0.210 (+3%) info
Market Cap: $714.99M info
AURA
Aug 11, 2026, 4:16 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.88
Real-time Price: $6.77 info
Change: -$1.11 (-14%) info
Market Cap: $714.99M info
AURA
Aug 11, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.36
Real-time Price: $6.77 info
Change: -$0.590 (-8%) info
Market Cap: $714.99M info
AURA
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.62
Real-time Price: $6.77 info
Change: -$0.850 (-11%) info
Market Cap: $714.99M info
AURA
Jul 08, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.73
Real-time Price: $6.77 info
Change: +$0.040 (+0.59%) info
Market Cap: $714.99M info
AURA
Jun 29, 2026, 5:28 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $6.88
Real-time Price: $6.77 info
Change: -$0.110 (-2%) info
Market Cap: $714.99M info
AURA
Jun 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $6.31
Real-time Price: $6.77 info
Change: +$0.460 (+7%) info
Market Cap: $714.99M info
AURA
Jun 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.47
Real-time Price: $6.77 info
Change: -$0.700 (-9%) info
Market Cap: $714.99M info
AURA
May 11, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.19
Real-time Price: $6.77 info
Change: -$1.42 (-17%) info
Market Cap: $714.99M info
AURA
May 11, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.19
Real-time Price: $6.77 info
Change: -$1.42 (-17%) info
Market Cap: $714.99M info
AURA
May 11, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $8.19
Real-time Price: $6.77 info
Change: -$1.42 (-17%) info
Market Cap: $714.99M info
AURA
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.19
Real-time Price: $6.77 info
Change: -$1.42 (-17%) info
Market Cap: $714.99M info
AURA
May 05, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.55
Real-time Price: $6.77 info
Change: -$1.78 (-21%) info
Market Cap: $714.99M info
AURA
May 05, 2026, 5:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.55
Real-time Price: $6.77 info
Change: -$1.78 (-21%) info
Market Cap: $714.99M info
AURA
May 04, 2026, 6:20 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $8.51
Real-time Price: $6.77 info
Change: -$1.74 (-20%) info
Market Cap: $714.99M info
AURA
May 04, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $6.77 info
Change: -$1.62 (-19%) info
Market Cap: $714.99M info
AURA
May 04, 2026, 7:30 AM EDT
Filing Type: S-3MEF
Importance Score:
8
Price at Filing: $7.00
Real-time Price: $6.77 info
Change: -$0.230 (-3%) info
Market Cap: $714.99M info
AURA
May 04, 2026, 6:55 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.60
Real-time Price: $6.77 info
Change: +$0.170 (+3%) info
Market Cap: $714.99M info
AURA
May 04, 2026, 6:18 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.61
Real-time Price: $6.77 info
Change: +$0.160 (+2%) info
Market Cap: $714.99M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets